Jung Soo Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jung Soo Kim has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Dong Jin Park
Department of Laboratory Medicine, Eunpyeong St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 03083, Republic of Korea
1 shared publication - Hyung-Jin Cho
Department of Surgery, Division of Vascular and Transplant Surgery, Eunpyeong St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
1 shared publication - Jehoon Lee
Department of Laboratory Medicine, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
1 shared publication - Juhwan Yoo
The Catholic University of Korea
1 shared publication - Mi-Hyeong Kim
Department of Surgery, Division of Vascular and Transplant Surgery, Eunpyeong St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
1 shared publication
Latest Publications
- Open Access
- 21 November 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (23) , 2948
Machine Learning-Based Algorithm for Tacrolimus Dose Optimization in Hospitalized Kidney Transplant Patients
Background: Tacrolimus is a cornerstone immunosuppressant in kidney transplantation, but its narrow therapeutic index and marked inter-patient variability complicate dose optimization. Conventional therapeutic drug monitoring (TDM) relies on empirical adjustments that often overlook individual pharmacokinetics. Machine learning (ML) offers a precision dosing alternative by integrating diverse clinical and biochemical variables into predictive models. Methods: We retrospectively analyzed 1351 data points from 87 kidney transplant patients at Eunpyeong St. Mary’s Hospital (April 2019–November 2023). Clinical, demographic, and laboratory information, including tacrolimus trough levels and dosing history, were extracted from electronic medical records. Four predictive models—XGBoost, CatBoost, LightGBM, and a multilayer perceptron (MLP)—were trained to forecast next-day tacrolimus concentrations, and model serum creatinine level performance was evaluated using R-squared (R2), mean absolute error (MAE), and root-mean-squared error (RMSE). An ensemble model with weighted soft voting was applied to enhance predictive accuracy, and model interpretability was assessed using SHapley Additive exPlanations (SHAP). Results: The ensemble model achieved the best overall performance (R2 = 0.6297, MAE = 1.0181, RMSE = 1.2999), outperforming all individual models, whereas the MLP model showed superior predictive power among single models, reflecting the significance of nonlinear interactions in tacrolimus pharmacokinetics. SHAP analysis highlighted prior tacrolimus levels, cumulative dose, renal function markers (eGFR level, serum creatinine level), and albumin concentration as the most influential predictors. Conclusions: We present a robust ML-based algorithm for tacrolimus dose optimization in hospitalized kidney transplant recipients. By improving predictions of tacrolimus concentrations, the model may help reduce inter-patient dose variability and lower the risk of nephrotoxicity, supporting safer and more individualized immunosuppressive management. This approach advances AI-driven precision medicine in transplant care, offering a pathway to safer and more effective immunosuppression.
- 21 November 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (23) , 2948
Open AccessMachine Learning-Based Algorithm for Tacrolimus Dose Optimization in Hospitalized Kidney Transplant Patients
Background: Tacrolimus is a cornerstone immunosuppressant in kidney transplantation, but its narrow therapeutic index and marked inter-patient variability complicate dose optimization. Conventional therapeutic drug monitoring (TDM) relies on empirical adjustments that often overlook individual pharmacokinetics. Machine learning (ML) offers a precision dosing alternative by integrating diverse clinical and biochemical variables into predictive models. Methods: We retrospectively analyzed 1351 data points from 87 kidney transplant patients at Eunpyeong St. Mary’s Hospital (April 2019–November 2023). Clinical, demographic, and laboratory information, including tacrolimus trough levels and dosing history, were extracted from electronic medical records. Four predictive models—XGBoost, CatBoost, LightGBM, and a multilayer perceptron (MLP)—were trained to forecast next-day tacrolimus concentrations, and model serum creatinine level performance was evaluated using R-squared (R2), mean absolute error (MAE), and root-mean-squared error (RMSE). An ensemble model with weighted soft voting was applied to enhance predictive accuracy, and model interpretability was assessed using SHapley Additive exPlanations (SHAP). Results: The ensemble model achieved the best overall performance (R2 = 0.6297, MAE = 1.0181, RMSE = 1.2999), outperforming all individual models, whereas the MLP model showed superior predictive power among single models, reflecting the significance of nonlinear interactions in tacrolimus pharmacokinetics. SHAP analysis highlighted prior tacrolimus levels, cumulative dose, renal function markers (eGFR level, serum creatinine level), and albumin concentration as the most influential predictors. Conclusions: We present a robust ML-based algorithm for tacrolimus dose optimization in hospitalized kidney transplant recipients. By improving predictions of tacrolimus concentrations, the model may help reduce inter-patient dose variability and lower the risk of nephrotoxicity, supporting safer and more individualized immunosuppressive management. This approach advances AI-driven precision medicine in transplant care, offering a pathway to safer and more effective immunosuppression.